Bull case
MapLight Therapeutics is viewed positively because ML-007C-MA targets two large central nervous system markets with substantial unmet need, including schizophrenia and Alzheimer’s disease psychosis, where no approved therapies exist for AD psychosis and a differentiated safety profile could support branded pricing despite generic competition. Its clinical profile is encouraging, with favorable safety and tolerability, high target-dose attainment, and potential differentiation from Cobenfy through dosing convenience and reduced peripheral side effects, while the recently completed Phase 2 enrollment and Fast Track designation in Dec 2025 strengthen the development story. The company also has multiple visible catalysts, including 2H 2026 FDA meetings for schizophrenia, a 1H 2027 estimated Phase 3 initiation, and a 2H 2027 VISTA topline readout, while the $150M PIPE financing provides near-term capital support.